Top Markets
#1 Siren Siren +45.30%
#2 Helium Helium +15.28%
#3 Cryptopia Cryptopia +9.12%
#4 Verus Coin Verus Coin +6.66%
#5 Useless Coin Useless Coin +5.99%
#6 OpenGradient OpenGradient +4.98%
#7 o1.exchange o1.exchange +4.73%
#8 Across Protocol Across Protocol +4.69%
#9 PondCoin PondCoin +4.47%
#10 Mubarak Mubarak +4.45%
Coin of the day
Siren Siren
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Jacobio Pharmaceuticals Group Co., Ltd. Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd.

1167
Classement en actions #11796
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm... Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
Prix de l'action
$0.84111496
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$657.90M
Changement (1 jour)
-0.75%
Changement (1 an)
-19.13%
Pays
CN
Échange Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Catégorie

Healthcare
Nombre d'actions en circulation pour Jacobio Pharmaceuticals Group Co., Ltd. (1167)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Jacobio Pharmaceuticals Group Co., Ltd., le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Jacobio Pharmaceuticals Group Co., Ltd. (1167) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH